Pharmaceutical Companies in Egypt
A comprehensive guide to the pharmaceutical industry in Egypt — the largest population in MENA and the strongest local manufacturing base in the region. Covering major pharma companies, EDA regulatory framework, 90% domestic production, market data, distribution channels, and strategic opportunities.
Last updated: February 2026 · Sources: EDA, BioNixus MEA, company filings, industry reports
Cite this guide
BioNixus. "Pharmaceutical Companies in Egypt: Complete Industry Guide 2026." BioNixus Healthcare Market Research, Feb. 2026, https://www.bionixus.com/pharmaceutical-companies-egypt.
Licensed under CC BY 4.0 — free to share and adapt with attribution.
$5.8B
Pharmaceutical market value
9.2%
Year-over-year growth
109.3M
Population
$53
Pharma spending per capita
Egypt Pharmaceutical Market Overview
Egypt has the largest population in MENA (109.3 million) and the strongest local pharmaceutical manufacturing base in the region. The market is valued at approximately US$5.8 billion, with 90% of medicines consumed produced domestically — only around 10% import dependency. Over 120 pharmaceutical companies operate in Egypt, with local manufacturers holding about 56% market share.
Per-capita pharmaceutical spending is $53, which is low but growing as Universal Health Insurance (UHI) and Hayah Karima expand, and the Egyptian Drug Authority (EDA), established in 2020, drives regulatory modernisation. Egypt is a generics powerhouse and an important African export hub.
The market is growing at 9.2% year-over-year, driven by UHI expansion, chronic disease burden, EDA reforms, and the scale of local manufacturing. Pricing is government-controlled via reference pricing, and drug registration typically takes 12–24 months with 5-year renewal.
For a broader regional comparison, see our MENA Pharmaceutical Market Data 2026 and GCC Pharmaceutical Market Access Guide.
Top Pharmaceutical Companies in Egypt
The following table lists the major pharmaceutical companies operating in Egypt — including local manufacturers, multinational corporation offices, regional players, and the largest distributor.
| Company | HQ |
|---|---|
| EIPICO (Egyptian International Pharmaceutical Industries Company) | Egypt |
| EVA Pharma | Egypt |
| Amoun Pharmaceutical | Egypt |
| Global Napi Pharma | Egypt |
| Minapharm Pharmaceuticals | Egypt |
| Pharco Corporation | Egypt |
| Egyptian Group for Pharmaceutical Industries | Egypt |
| Memphis Pharmaceuticals | Egypt |
| Kahira Pharmaceuticals | Egypt |
| Alexandria Pharma (AXPH) | Egypt |
| Pfizer | USA |
| Novartis | Switzerland |
| Sanofi | France |
| AstraZeneca | UK / Sweden |
| GSK (GlaxoSmithKline) | UK |
| Roche | Switzerland |
| MSD (Merck & Co.) | USA |
| AbbVie | USA |
| Hikma Pharmaceuticals | Jordan / UK |
| Ibn Sina Pharma | Egypt |
List of Pharmaceutical Companies in Egypt by Category
Egypt pharmaceutical companies span local manufacturers (90% domestic production), multinational corporations with offices, regional players, and the largest nationwide distributor.
Local Manufacturers
Egypt has over 120 pharmaceutical companies with roughly 90% of the market supplied by local production. Leaders include EIPICO (largest private, 54 lines, 310M packs/yr), EVA Pharma (40+ countries), Minapharm (biotech leader since 1958), Pharco (HCV leader), and Alexandria Pharma (oldest).
- ✓ EIPICO (Egyptian International Pharmaceutical Industries Company)
- ✓ EVA Pharma
- ✓ Amoun Pharmaceutical
- ✓ Global Napi Pharma
- ✓ Minapharm Pharmaceuticals
- ✓ Pharco Corporation
- ✓ Egyptian Group for Pharmaceutical Industries
- ✓ Memphis Pharmaceuticals
- ✓ Kahira Pharmaceuticals
- ✓ Alexandria Pharma (AXPH)
Multinational Pharma Offices
Major global pharmaceutical companies maintain offices in Egypt. Pfizer, Novartis, Sanofi (with local production), AstraZeneca, GSK, Roche, MSD, and AbbVie are key MNCs in the market, serving the innovator segment alongside strong local generics.
- ✓ Pfizer
- ✓ Novartis
- ✓ Sanofi
- ✓ AstraZeneca
- ✓ GSK (GlaxoSmithKline)
- ✓ Roche
- ✓ MSD (Merck & Co.)
- ✓ AbbVie
Regional Pharma Companies
Regional player Hikma Pharmaceuticals (Jordan/UK) has a strong presence in Egypt, with injectables and generics across MENA.
- ✓ Hikma Pharmaceuticals
Distributors
Retail pharmacy is the dominant channel with 80,000+ pharmacies. Ibn Sina Pharma is the largest distributor in Egypt with nationwide coverage.
- ✓ Ibn Sina Pharma
Pharma Companies in Egypt: EDA Regulatory Landscape
The Egyptian Drug Authority (EDA), established in 2020, oversees pharmaceutical registration, quality control, pricing, and pharmacovigilance, and is driving regulatory modernisation.
Regulatory Authority
The Egyptian Drug Authority (EDA), established in 2020, oversees all pharmaceutical registration, quality control, pricing, pharmacovigilance, and import licensing. Egypt uses government-controlled reference pricing.
Registration Timeline
12–24 months
Renewal Period
5 years
Pricing Model
Government-controlled reference pricing
Key Registration Requirements
- ✓Full dossier submission via EDA
- ✓GMP certificates and compliance
- ✓Stability data for local climate conditions
- ✓Arabic labelling mandatory on all products
- ✓Clinical trial data and bioequivalence studies (generics)
- ✓Certificate of Pharmaceutical Product (CPP) where applicable
Local Manufacturing & Export
Approximately 90% of medicines consumed in Egypt are produced domestically; only around 10% are imported. The EDA supports local manufacturing and Egypt's role as an African export hub. For regional registration details, see our GCC Pharmaceutical Market Access Guide and MENA Pharmaceutical Market Data 2026.
Drug Distribution Channels in Egypt
Egypt's pharmaceutical distribution is dominated by retail pharmacy, with government and private hospitals also key channels.
Retail Pharmacy (Dominant)
With 80,000+ pharmacies, retail pharmacy is the dominant distribution channel in Egypt. Ibn Sina Pharma is the largest distributor with nationwide coverage.
- ► 80,000+ pharmacies nationwide
- ► Ibn Sina Pharma — largest distributor
- ► OTC and prescription dispensing
Hospitals (Government & Private)
Government hospitals serve a large share of the population; private hospitals are growing as UHI and Hayah Karima expand access and investment.
- ► Government hospital procurement
- ► Private hospitals growing
- ► UHI expansion driving utilisation
Egypt Pharmaceutical Market Growth Drivers
Universal Health Insurance, demographics, local manufacturing strength, and regulatory reform are driving growth in Egypt's pharmaceutical sector.
Universal Health Insurance (Hayah Karima)
UHI and Hayah Karima are expanding coverage across Egypt, driving pharmaceutical utilisation and improving access for the largest population in MENA (109.3M).
Largest MENA Population
With 109.3 million people, Egypt offers the largest addressable pharmaceutical market in the region, with per-capita spending ($53) low but growing.
Local Manufacturing Strength (90% Domestic)
Roughly 90% of medicines are produced locally; 120+ companies and 56% local market share make Egypt the strongest local manufacturing base in MENA.
EDA Regulatory Modernisation
The Egyptian Drug Authority (established 2020) is modernising regulation, improving predictability and alignment with international standards for market access.
African Export Hub
Egypt is a key export hub for pharmaceuticals into Africa, leveraging local manufacturing capacity and trade agreements.
Chronic Disease Burden
Rising chronic disease burden drives sustained demand for generics and specialty therapies, supporting both local manufacturers and MNCs.
How BioNixus Supports Pharma Companies in Egypt
BioNixus is a leading healthcare market research company with deep expertise in the Egyptian pharmaceutical market. We help pharma, biotech, and medtech companies with:
Physician Surveys & KOL Mapping
Large-scale quantitative and qualitative research with Egyptian physicians across government and private hospitals. Arabic-English bilingual capabilities.
Market Access & EDA Strategy
EDA formulary strategy, competitive pricing analysis, reimbursement landscape, and payer research to optimise commercial success in Egypt.
Competitive Intelligence
Real-time monitoring of competitor launches, tender outcomes, formulary changes, and market share across all therapeutic areas.
Market Entry Strategy
Comprehensive market assessment including regulatory pathway analysis, local partner identification, KOL engagement, and go-to-market planning for the Egyptian market.
Frequently Asked Questions
How many pharmaceutical companies operate in Egypt?
Egypt has over 120 pharmaceutical companies, including local manufacturers, multinational offices, and distributors. The market is valued at approximately $5.8 billion, with local manufacturers holding around 56% market share. Egypt has the strongest local manufacturing base in MENA, with roughly 90% of medicines consumed produced domestically.
What is the size of Egypt's pharmaceutical market?
Egypt's pharmaceutical market is valued at approximately US$5.8 billion, with 9.2% year-over-year growth. With a population of 109.3 million — the largest in MENA — per-capita pharmaceutical spending is about $53, which is low but growing as Universal Health Insurance (Hayah Karima) expands and the EDA modernises regulation.
What is the EDA (Egyptian Drug Authority)?
The Egyptian Drug Authority (EDA) is Egypt's national pharmaceutical regulator, established in 2020. It oversees drug registration, quality control, pricing, pharmacovigilance, and import licensing. The EDA is driving regulatory modernisation to align with international standards and support the country's position as a generics powerhouse and African export hub.
How dominant is local pharmaceutical manufacturing in Egypt?
Egypt has the strongest local pharmaceutical manufacturing in MENA: approximately 90% of medicines consumed are produced domestically. Over 120 companies operate in the market, with local manufacturers holding about 56% market share. Only around 10% of the market is import-dependent, making Egypt a generics powerhouse and key African export hub.
How does pharmaceutical pricing work in Egypt?
Egypt uses government-controlled reference pricing. The EDA oversees pricing decisions, which are benchmarked to control affordability while supporting local manufacturing. This mechanism helps maintain access for the large population while encouraging domestic production.
How long does drug registration take with the EDA?
Drug registration with the Egyptian Drug Authority (EDA) typically takes 12–24 months. Registration requires a full dossier, GMP certification, stability data, and compliance with EDA requirements. Licences are renewed on a 5-year basis.
Data Sources & Methodology
This guide aggregates publicly available information from:
- BioNixus Middle East & Africa Pharmaceutical Market Report
- Egyptian Drug Authority (EDA) — regulatory and market data
- Company filings and annual reports (EIPICO, EVA Pharma, Minapharm, Pharco, etc.)
- Industry reports on Egyptian pharma and distribution
- BioNixus proprietary research from physician surveys in Egypt (2024–2025)
For customised market intelligence on Egypt, contact our team.
Need Market Intelligence on Egypt?
BioNixus delivers custom pharmaceutical market research across Egypt and MENA — physician surveys, competitive intelligence, market access strategy, and KOL mapping.